29.03.2011 • NewsBiosimilarsTevaNovartis

Biosimilars Seen as a $3.7 billion Drug Market by 2015

The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as a raft of branded drugs lose patent cover, according to market analysis firm Datamonitor.

Many drugmakers are seeing potential in the business of producing copycat versions of expensive biotechnology drugs as regulators draft new rules for their approval.

Because of the complexity of such drugs, which are produced through biological processes that generally involve recombinant DNA technologies, they are known as "biosimilars" rather than generics.

Europe has led the way in setting out guidelines for biosimilars but U.S. regulations are also in the works and Japan, too, is addressing the issue.

Impetus for biosimilars will come from the fact that more than 30 branded biologics with sales of $51 billion are set to lose patent exclusivity between 2011 and 2015, Datamonitor said on Monday.

A number of generic drugmakers have made biosimilars a priority for future growth, including Teva, Novartis unit Sandoz and Hospira. They are being joined by several branded drugmakers, such as Merck.

In their sights are current blockbuster biotech treatments from companies including Roche and Amgen.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.